

Flavonoid Glycosides from the Seeds of *Litchi chinensis*Xinya Xu,^{†,‡} Haihui Xie,^{*,†} Jing Hao,[†] Yueming Jiang,[†] and Xiaoyi Wei[†][†]Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences, Guangzhou 510650, People's Republic of China[‡]Graduate University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

ABSTRACT: Seven flavonoid glycosides, including one new (1) and five previously uncharacterized (3–7), were obtained from the seeds of lychee (*Litchi chinensis* Sonn. cv. Heiye) by means of repetitive column chromatography and high-performance liquid chromatography (HPLC) preparation. They were identified as litchioside D (1), (–)-pinocembrin 7-O-neohesperidoside (2), (–)-pinocembrin 7-O-rutinoside (3), taxifolin 4'-O-β-D-glucopyranoside (4), kaempferol 7-O-neohesperidoside (5), tamarixetin 3-O-rutinoside (6), and phlorizin (7) on the basis of spectroscopic analysis and comparison of their data to the values reported in the literatures. Among them, compounds 1, 4, and 5 showed *in vitro* antitumor activity against A549, LAC, Hep-G2, and HeLa cell lines in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay.

KEYWORDS: *Litchi chinensis*, lychee seed, flavonoid glycoside, litchioside D, cytotoxic activity

■ INTRODUCTION

Lychee (*Litchi chinensis* Sonn.), the only member of the genus *Litchi* in the family Sapindaceae, is a subtropical tree native to China and now cultivated in many parts of the world. Its fruits are popular in domestic and overseas markets because of their edible and delicious arils and attractive appearance. The annual output of lychee fruits in China exceeds 1.3×10^9 kg. As a byproduct of the fruits, lychee seeds are mainly discarded as waste, although they are used as a traditional Chinese medicine for the treatment of epigastric pain and testicular swelling and pain.^{1,2} Pharmacological studies revealed that lychee seeds possessed antihyperglycemic, antihyperlipidemic, antiplatelet aggregation, antitumor, antiviral, and antioxidant effects.^{3–5} However, reports concerning their biologically active components remain very scarce.^{6,7} To clarify the structures and bioactivities of uncharacterized components, we carried out further chemical investigation on the seeds. In previous papers, we reported four eudesmane sesquiterpene glucosides and their cytotoxic activity⁸ and seven A-type proanthocyanidins and two related compounds and their antioxidant and antiviral activities.⁹ As a continuation of this work, we describe the isolation and identification of seven flavonoid glycosides and their *in vitro* antitumor activity in the present paper.

■ MATERIALS AND METHODS

General Methods. Optical rotations were measured on a Perkin-Elmer 343 polarimeter (Perkin-Elmer, Inc., Waltham, MA). Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DRX-400 NMR spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany) with the solvent residual peaks of dimethyl sulfoxide (DMSO)-*d*₆ at δ_{H} 2.50 and δ_{C} 39.52 as references. High-resolution electrospray ionization mass spectrometry (HRESIMS) was obtained on a Bruker Bio TOF IIIQ mass spectrometer (Bruker Daltonics, Inc., Billerica, MA), and electrospray ionization mass spectrometry (ESIMS) data were acquired on a MDS SCIEX API 2000 liquid chromatography/tandem mass spectrometry (LC/MS/MS) instrument (Applied Biosystems, Inc., Forster, CA). Column chromatography was performed over silica gel

(100–200 mesh, Qingdao Haiyang Chemical Co., Ltd., Qingdao, China), Develosil ODS (S-75 μm , Nomura Chemical Co., Ltd., Seto, Japan), macroporous resin Diaion HP-20 (Mitsubishi Chemical Corporation, Tokyo, Japan), and Sephadex LH-20 (Amersham Biosciences, Uppsala, Sweden). High-performance liquid chromatography (HPLC) was carried out on a Shimadzu LC-6AD liquid chromatograph equipped with a Shimadzu RID-10A refractive index detector (Shimadzu Corp., Kyoto, Japan). YMC-Pack ODS-A columns (S-5 μm , 250 \times 4.6 mm and 250 \times 20 mm inner diameter, YMC Co., Ltd., Kyoto, Japan) were used for analytical and preparative purposes, respectively. Thin-layer chromatography (TLC) was conducted on precoated silica gel HSGF₂₅₄ plates (Yantai Jiangyou Silica Gel Development Co., Ltd., Yantai, China) and reversed-phase (RP)-18 F_{254S} plates (Merck Japan Ltd., Tokyo, Japan), and spot detection was performed under fluorescent light ($\lambda = 254$ and 365 nm) and then spraying 10% H₂SO₄ in EtOH, followed by heating. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and naringinase were purchased from Sigma Chemical Co. (St. Louis, MO). Roswell Park Memorial Institute (RPMI)-1640 medium and admycin were purchased from Gibco BRL (Gaithersburg, MD) and Shenzhen Main Luck Pharmaceutical, Inc. (Shenzhen, China), respectively. Fetal calf serum was obtained from Guangzhou Jinan Biomedicine Research and Development Center (Guangzhou, China).

Plant Material. Lychee (*L. chinensis* cv. Heiye) fruits at commercial maturity were collected from an orchard in Luogang District, Guangzhou, China, in July 2007. A voucher specimen was deposited at the Herbarium of South China Botanical Garden, Chinese Academy of Sciences, Guangzhou, China. The seeds were manually separated and ground to pieces with a Santronic multifood processor.

Extraction and Isolation. Fresh lychee seed pieces (6,150 g) were extracted 3 times with 95% EtOH (10 L \times 3) at room temperature (25–32 °C) for 4 days each time. The concentration of the solution under vacuum gave a reddish solid (934.86 g), of which 906.34 g was

Received: November 13, 2010

Accepted: January 7, 2011

Revised: January 6, 2011

Published: February 2, 2011

dissolved in 0.8 L of water and then successively partitioned with petroleum ether (0.8 L \times 5), ethyl acetate (EtOAc, 0.8 L \times 5), and *n*-butanol (*n*-BuOH, 0.8 L \times 5) to afford petroleum-ether-soluble (38.80 g), EtOAc-soluble (91.65 g), and *n*-BuOH-soluble (151.60 g) fractions after condensation to dryness *in vacuo*. The petroleum-ether-soluble fraction (38.80 g) was subjected to silica gel (822 g) column (72 mm inner diameter \times 490 mm) chromatography eluted with CHCl₃/MeOH [10:0, 9.5:0.5, 9:1, 8.5:1.5, 8:2, and 7:3 (vol/vol) at 9.0, 11.0, 12.0, 17.5, 10.0, and 7.5 L, respectively] to gain fractions P1–P11 after pooling according to their TLC profiles. Fraction P8 (2.10 g), obtained from the elution of CHCl₃/MeOH of 8.5:1.5, was passed through a Develosil ODS (4.2 g) precolumn, and the 80% MeOH/H₂O (vol/vol) eluate (0.29 g) was separated by Develosil ODS (5.8 g) column (12 mm inner diameter \times 105 mm) chromatography eluted with MeOH/H₂O [1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, and 8:2 (vol/vol) at 60 mL each] to gain fractions P8-1–P8-8. Fraction P8-4 (28 mg) was submitted to Sephadex LH-20 column chromatography eluted with MeOH to yield compound 7 (10.7 mg, 0.000 18%). The *n*-BuOH-soluble fraction (141.20 g) was dissolved in water and passed through a HP-20 (2800 g) column sequentially eluted with H₂O and MeOH. The MeOH eluate (80.80 g) was subjected to silica gel (1600 g) column (92 mm inner diameter \times 590 mm) chromatography eluted with CHCl₃/MeOH [9:1, 8.5:1.5, 8:2, 7:3, and 6:4 (vol/vol) at 14 L each] to attain fractions B1–B6. Fraction B3 (2.23 g), obtained from the elution of CHCl₃/MeOH of 8.5:1.5 and 8:2, was separated by Develosil ODS (45.0 g) column (18 mm inner diameter \times 360 mm) chromatography eluted with MeOH/H₂O [1:9, 2:8, 3:7, 4:6, 5:5, 6:4, and 7:3 (vol/vol) at 450 mL each] to give fractions B3-1–B3-35. Fractions B3-21 and B3-22 (178.9 mg) were purified by HPLC using 49% MeOH/H₂O (v/v) as the mobile phase at the flow rate of 5 mL/min to offer compound 2 (*t*_R at 59.8 min, 8.2 mg, 0.000 15%), compound 3 (*t*_R at 54.1 min, 8.6 mg, 0.000 15%), and compound 6 (*t*_R at 41.4 min, 21.6 mg, 0.000 39%). Fraction B5 (1.43 g), obtained from the elution of CHCl₃/MeOH of 8:2 and 7:3, was separated by Develosil ODS (28.8 g) column (18 mm inner diameter \times 230 mm) chromatography eluted with MeOH/H₂O [1:9, 2:8, 3:7, 4:6, 5:5, and 6:4 (vol/vol) at 300 mL each] to afford fractions B5-1–B5-30. Fractions B5-8 and B5-9 (76.9 mg) were separated by Sephadex LH-20 column chromatography eluted with MeOH to yield compound 4 (39.0 mg, 0.000 70%). Fractions B5-18–B5-21 (348.2 mg) were separated by Sephadex LH-20 column chromatography eluted with MeOH to supply compound 5 (7.1 mg, 0.000 13%) and a residue, which was purified by HPLC using 48% MeOH/H₂O (vol/vol) as the mobile phase at the flow rate of 5 mL/min to provide compound 1 (*t*_R at 51.9 min, 15.3 mg, 0.000 28%).

Litchioside D (1). Yellowish powder. [α]_D²⁰ – 95.3 (*c* 0.60, MeOH). ¹H NMR (DMSO-*d*₆, 400 MHz) δ : 5.66 (1H, dd, *J* = 2.8, 12.1 Hz, H-2), 3.17 (1H, dd, *J* = 12.1, 16.9 Hz, H-3a), 2.84 (1H, dd, *J* = 2.8, 16.9 Hz, H-3b), 12.00 (1H, br s, OH-5), 6.12 (1H, d, *J* = 1.8 Hz, H-6), 6.14 (1H, d, *J* = 1.8 Hz, H-8), 7.54 (2H, dd, *J* = 1.8, 7.6 Hz, H-2', H-6'), 7.44 (2H, dd, *J* = 7.6, 7.6 Hz, H-3', H-5'), 7.38 (1H, m, H-4'), 5.17 (1H, d, *J* = 7.6 Hz, H-1''), 3.44 (1H, m, H-2''), 3.52 (1H, dd, *J* = 8.9, 9.1, H-3''), 3.20 (1H, m, H-4''), 3.62 (1H, m, H-5''), 3.44 (1H, m, H-6''a), 3.79 (1H, dd, *J* = 3.8, 10.2 Hz, H-6''b), 5.07 (1H, d, *J* = 2.8 Hz, H-1'''), 3.58 (1H, m, H-2'''), 3.47 (1H, d, *J* = 3.0 Hz, H-3'''), 3.44 (1H, m, H-4'''), 3.89 (1H, q, *J* = 6.4 Hz, H-5'''), 1.03 (3H, d, *J* = 6.5 Hz, H-6'''), 4.52 (1H, br s, H-1'''), 3.65 (1H, m, H-2'''), 3.44 (1H, m, H-3'''), 3.15 (1H, dd, *J* = 3.2, 8.4 Hz, H-4'''), 3.40 (1H, m, H-5'''), 1.08 (3H, d, *J* = 5.7 Hz, H-6'''). ¹³C NMR (DMSO-*d*₆, 100 MHz): see Table 1. ESIMS (+) *m/z*: 711 [M + H]⁺, 733 [M + Na]⁺; (–) *m/z*: 255 [M – glucosyl – rhamnosyl – H][–], 709 [M – H][–], 745 [M + Cl][–]. HRESIMS (–) *m/z*: 745.2134 [M + Cl][–] (calculated for C₃₃H₄₂ClO₁₇[–], 745.2116).

(–)-Pinocembrin 7-O-Neohesperidoside (2). Yellowish powder. [α]_D²⁰ – 34.0 (*c* 0.05, MeOH). ¹H NMR (DMSO-*d*₆, 400 MHz) δ : 5.66

Table 1. ¹³C NMR Data for Compounds 1–3 and (–)-Pinocembrin 7-O- β -D-Glucopyranoside (1a) in DMSO-*d*₆

C	1	1a ¹¹	2	3
2	78.52	78.67	78.64	79.07
3	42.05	42.20	42.18	42.29
4	196.82	196.89	196.83	196.46
5	162.55	162.58	162.92	162.40
6	96.48	96.66	96.53	96.62
7	164.90	165.37	165.06	165.02
8	95.21	95.54	95.21	95.38
9	163.07	162.98	162.63	162.35
10	103.47	103.31	103.39	103.39
1'	138.47	138.50	138.48	138.39
2'	126.82	126.80	126.74	126.61
3'	128.64	128.64	128.63	128.44
4'	128.64	128.72	128.70	128.47
5'	128.64	128.64	128.63	128.44
6'	126.82	126.80	126.74	126.61
1''	97.60	99.58	97.77	99.41
2''	79.76	73.04	79.92	72.94
3''	76.54	76.33	77.06	76.26
4''	69.33	69.48	69.20	69.62
5''	75.50	77.11	76.60	75.56
6''	65.94	60.57	60.43	65.99
1''' (2''-Rha)	100.73		100.73	
2''' (2''-Rha)	68.60		68.62	
3''' (2''-Rha)	69.70		69.71	
4''' (2''-Rha)	71.65		71.65	
5''' (2''-Rha)	66.39		66.38	
6''' (2''-Rha)	16.54		16.52	
1'''' (6''-Rha)	100.65			100.52
2'''' (6''-Rha)	70.29			70.19
3'''' (6''-Rha)	70.72			70.67
4'''' (6''-Rha)	72.09			72.05
5'''' (6''-Rha)	68.37			68.20
6'''' (6''-Rha)	17.85			17.68

(1H, dd, *J* = 2.8, 12.5 Hz, H-2), 3.20 (1H, dd, *J* = 12.5, 17.2 Hz, H-3a), 2.84 (1H, dd, *J* = 2.8, 17.2 Hz, H-3b), 12.02 (1H, br s, OH-5), 6.10 (1H, d, *J* = 2.0 Hz, H-6), 6.18 (1H, d, *J* = 2.0 Hz, H-8), 7.53 (2H, dd, *J* = 1.6, 7.5 Hz, H-2', H-6'), 7.44 (2H, dd, *J* = 7.5, 7.5 Hz, H-3', H-5'), 7.39 (1H, m, H-4'), 5.15 (1H, d, *J* = 7.7 Hz, H-1''), 5.07 (1H, d, *J* = 3.6 Hz, H-1'''), 1.03 (3H, d, *J* = 6.5 Hz, H-6'''). ¹³C NMR (DMSO-*d*₆, 100 MHz): see Table 1. ESIMS (+) *m/z*: 257 [M – glucosyl – rhamnosyl + H]⁺, 587 [M + Na]⁺; (–) *m/z*: 255 [M – glucosyl – rhamnosyl – H][–], 563 [M – H][–], 599 [M + Cl][–].

(–)-Pinocembrin 7-O-Rutinoside (3). Yellowish powder. [α]_D²⁰ – 31.4 (*c* 0.53, MeOH). ¹H NMR (DMSO-*d*₆, 400 MHz) δ : 5.66 (1H, dd, *J* = 3.0, 12.2 Hz, H-2), 3.22 (1H, dd, *J* = 12.2, 17.2 Hz, H-3a), 2.85 (1H, dd, *J* = 3.0, 17.2 Hz, H-3b), 11.96 (1H, br s, OH-5), 6.14 (2H, br s, H-6, H-8), 7.54 (2H, dd, *J* = 1.6, 7.7 Hz, H-2', H-6'), 7.44 (2H, dd, *J* = 7.7, 7.7 Hz, H-3', H-5'), 7.39 (1H, m, H-4'), 4.98 (1H, d, *J* = 7.4 Hz, H-1''), 4.52 (1H, br s, H-1'''), 1.08 (3H, d, *J* = 6.2 Hz, H-6'''). ¹³C NMR (DMSO-*d*₆, 100 MHz): see Table 1. ESIMS (+) *m/z*: 587 [M + Na]⁺; (–) *m/z*: 255 [M – glucosyl – rhamnosyl – H][–], 563 [M – H][–], 599 [M + Cl][–].

Taxifolin 4'-O- β -D-Glucopyranoside (4). Yellowish powder. [α]_D²⁰ – 20.4 (*c* 0.58, MeOH). ¹H NMR (DMSO-*d*₆, 400 MHz) δ : 5.82 (1H, dd, *J* = 11.2 Hz, H-2), 5.04 (1H, d, *J* = 11.2 Hz, H-3), 11.89 (1H, br s, OH-5), 5.86 (1H, d, *J* = 1.8 Hz, H-6), 8.71 (1H, br s, OH-7),

5.90 (1H, d, $J = 1.8$ Hz, H-8), 6.96 (1H, d, $J = 1.8$ Hz, H-2'), 7.12 (1H, d, $J = 8.4$ Hz, H-5'), 6.87 (1H, dd, $J = 1.8, 8.4$ Hz, H-6'), 4.70 (1H, d, $J = 7.1$ Hz, H-1''). ^{13}C NMR (DMSO- d_6 , 100 MHz) δ : 82.68 (C-2), 71.51 (C-3), 197.67 (C-4), 163.35 (C-5), 96.11 (C-6), 166.92 (C-7), 95.08 (C-8), 162.48 (C-9), 100.48 (C-10), 131.83 (C-1'), 115.64 (C-2'), 146.55 (C-3'), 145.61 (C-4'), 116.36 (C-5'), 119.33 (C-6'), 102.24 (C-1''), 73.34 (C-2''), 77.24 (C-3''), 69.86 (C-4''), 75.93 (C-5''), 60.80 (C-6''). ESIMS (+) m/z : 288 [M - glucosyl + H] $^+$, 489 [M + Na] $^+$; (−) m/z : 465 [M - H] $^-$, 501 [M + Cl] $^-$.

Kaempferol 7-O-Neohesperidoside (5). Yellowish powder. $[\alpha]_D^{20} - 57.2$ (c 0.14, MeOH). ^1H NMR (DMSO- d_6 , 400 MHz) δ : 12.50 (1H, br s, OH-5), 6.37 (1H, br s, H-6), 6.79 (1H, br s, H-8), 8.06 (2H, d, $J = 8.6$ Hz, H-2', H-6'), 6.94 (2H, d, $J = 8.6$ Hz, H-3', H-5'), 5.24 (1H, d, $J = 7.6$ Hz, H-1''), 5.09 (1H, d, $J = 3.3$ Hz, H-1'''), 1.02 (3H, d, $J = 6.3$ Hz, H-6'''). ^{13}C NMR (DMSO- d_6 , 100 MHz) δ : 147.65 (C-2), 136.11 (C-3), 176.14 (C-4), 160.42 (C-5), 98.63 (C-6), 162.47 (C-7), 94.16 (C-8), 155.82 (C-9), 104.82 (C-10), 121.55 (C-1'), 129.70 (C-2'), 115.56 (C-3'), 159.46 (C-4'), 115.56 (C-5'), 129.70 (C-6'), 98.13 (C-1''), 80.21 (C-2''), 77.17 (C-3''), 69.28 (C-4''), 76.67 (C-5''), 60.51 (C-6''), 100.89 (C-1'''), 68.69 (C-2'''), 69.74 (C-3'''), 71.67 (C-4'''), 66.48 (C-5'''), 16.52 (C-6'''). ESIMS (+) m/z : 595 [M + H] $^+$, 617 [M + Na] $^+$; (−) m/z : 285 [M - glucosyl - rhamnosyl - H] $^-$, 593 [M - H] $^-$, 629 [M + Cl] $^-$.

Tamarixetin 3-O-Rutinoside (6). Yellowish powder. $[\alpha]_D^{20} - 65.3$ (c 0.48, MeOH). ^1H NMR (DMSO- d_6 , 400 MHz) δ : 12.59 (1H, br s, OH-5), 6.22 (1H, d, $J = 1.5$ Hz, H-6), 10.97 (1H, br s, OH-7), 6.43 (1H, d, $J = 1.5$ Hz, H-8), 7.50 (1H, d, $J = 1.8$ Hz, H-2'), 7.03 (1H, d, $J = 8.5$ Hz, H-5'), 7.71 (1H, dd, $J = 1.8, 8.5$ Hz, H-6'), 3.85 (3H, s, OCH $_3$), 5.37 (1H, d, $J = 7.0$ Hz, H-1''), 4.40 (1H, br s, H-1'''), 0.98 (3H, d, $J = 6.0$ Hz, H-6'''). ^{13}C NMR (DMSO- d_6 , 100 MHz) δ : 156.42 (C-2), 133.64 (C-3), 177.46 (C-4), 161.23 (C-5), 98.81 (C-6), 164.30 (C-7), 93.71 (C-8), 156.51 (C-9), 104.04 (C-10), 121.53 (C-1'), 111.42 (C-2'), 150.10 (C-3'), 145.91 (C-4'), 115.69 (C-5'), 122.52 (C-6'), 55.66 (OCH $_3$), 101.31 (C-1''), 74.10 (C-2''), 76.44 (C-3''), 69.81 (C-4''), 75.80 (C-5''), 66.86 (C-6''), 100.81 (C-1'''), 70.40 (C-2'''), 70.65 (C-3'''), 71.86 (C-4'''), 68.29 (C-5'''), 17.77 (C-6'''). ESIMS (+) m/z : 625 [M + H] $^+$, 647 [M + Na] $^+$; (−) m/z : 315 [M - glucosyl - rhamnosyl - H] $^-$, 623 [M - H] $^-$, 659 [M + Cl] $^-$.

Enzymtic Hydrolysis of Compound 1. A solution of compound **1** (2.8 mg) and naringinase from *Penicillium decumbens* (Product N1385, 390 IU/g, 2 mg) in 1 mL of acetate buffer (pH 4.4) was stirred at 38 °C for 4 h. The reaction solution was extracted with ethyl ether (1 mL \times 3) after neutralization with 0.1 M NaOH. The concentration of the combined ethyl ether solution yielded a residue, which was separated by silica gel column chromatography eluted with CHCl $_3$ /MeOH (9:1, vol/vol) to afford compound **1a** (1.0 mg),¹⁰ which was identified as (−)-pinocembrin by a comparison of its ESIMS and ^1H NMR data and $[\alpha]_D^{20} - 46.8$ (c 0.08, CHCl $_3$) to those reported in the literature.¹¹

Cytotoxic Assay. Human lung cancer A549, human pulmonary carcinoma LAC, human hepatoma Hep-G2, and human cervical carcinoma HeLa cell lines were generously provided by Guangzhou Jinan Biomedicine Research and Development Center, Guangzhou, China. The cells were maintained in RPMI-1640 medium plus 10% heat-inactivated fetal bovine serum in a humidified atmosphere with 5% CO $_2$ at 37 °C. The cytotoxic activity of compounds **1–7** was determined using the MTT colorimetric assay as previously described by Mosmann.¹² Briefly, cancer cells were seeded into wells of a 96-well flat-bottom microtiter plate at 5×10^4 cell/mL in 195 μL of culture medium. A serial 2-fold dilution of test compounds was made in DMSO. Each serial solution of 5 μL was added to a well, including 195 μL of cell culture medium. The final concentrations of each test compound were 6.25, 12.5, 25, 50, and 100 μM . The plate was incubated at 37 °C in a humidified atmosphere with 5% CO $_2$. After 72 h, 10 μL of 5 mg/mL MTT solution was added to each well and incubated for 4 h. The

supernatant was carefully removed by pipet, and then 200 μL of DMSO solution was added to each well and shaken for 15 min to dissolve formazan crystals. The absorbance was measured on a Bio-Rad model 550 microplate reader (Bio-Rad Laboratories, Hercules, CA) at the wavelength of 570 nm. MTT solution with DMSO (without both cells and medium) was used as a blank control, and admycin was used as a reference control. The cytotoxic activity of test compounds to proliferation of A549, LAC, Hep-G2, and HeLa cells was calculated by SPSS 16.0 analytic software according to the following formula: cytotoxic activity (%) = (A_{570} of control cells − A_{570} of treated cells)/ A_{570} of control cells \times 100%. The 50% inhibitory concentration (IC $_{50}$) was defined as the concentration required to reduce the viability of untreated cell cultures by 50%.

RESULTS AND DISCUSSION

The EtOH extract of lychee seeds was dissolved in water and then sequentially partitioned with petroleum ether, EtOAc, and *n*-BuOH. The resulting petroleum-ether- and *n*-BuOH-soluble fractions were separated by repetitive column chromatography over silica gel, Develosil ODS, and Sephadex LH-20 and preparative HPLC to yield seven flavonoid glycosides (**1–7**).

Compound **1** was obtained as a yellowish powder with negative optical rotation. Its molecular formula was deduced to be C $_{33}$ H $_{42}$ O $_{17}$ from quasi-molecular ion peaks at m/z 711 [M + H] $^+$ and 709 [M − H] $^-$ in the ESIMS spectrum in combination with its NMR data as well as a negative-ion peak at 745.2134 [M + Cl] $^-$ in the HRESIMS spectrum. The ^1H NMR spectrum showed two *meta*-coupling doublets at δ 6.12 and 6.14 (1H each, $J = 1.8$ Hz, H-6, H-8), five aromatic protons at δ 7.38 (1H, m, H-4'), 7.44 (2H, dd, $J = 7.6, 7.6$ Hz, H-3', H-5'), and 7.54 (2H, dd, $J = 1.8, 7.6$ Hz, H-2', H-6'), and three aliphatic doublets at δ 5.66 (1H, $J = 2.8, 12.1$ Hz, H-2), 3.17 (1H, $J = 12.1, 16.9$ Hz, H-3a), and 2.84 (1H, $J = 2.8, 16.9$ Hz, H-3b), suggesting the presence of a pinocembrin moiety.¹¹ Moreover, the spectrum exhibited three anomeric protons at δ 5.17 (1H, d, $J = 7.6$ Hz, H-1''), 5.07 (1H, d, $J = 2.8$ Hz, H-1'''), and 4.52 (1H, br s, H-1''') and two methyls at δ 1.03 (3H, d, $J = 6.5$ Hz, H-6''') and 1.08 (3H, d, $J = 5.7$ Hz, H-6'''), suggesting a β -glucosyl and two α -rhamnosyl moieties. As shown in Table 1, the ^{13}C NMR spectrum presented signals of a carbonyl at δ 196.82 (C-2), 12 aromatic carbons at δ 95.21 (C-8), 96.48 (C-6), 103.47 (C-10), and 126.82–164.90, 3 anomeric carbons at δ 100.73 (C-1''), 100.65 (C-1'''), and 97.60 (C-1'''), 14 oxygenated carbons ranging from δ 65.94 to 79.76, an aliphatic methylene at δ 42.05 (C-3), and 2 methyls at δ 17.85 and 16.54. These data indicated that compound **1** was a pinocembrin triglycoside. This was supported by enzymatic hydrolysis of compound **1** with naringinase, which yielded (−)-pinocembrin. In comparison to the data of (−)-pinocembrin 7-O- β -D-glucopyranoside,¹¹ carbon resonances for the pinocembrin skeleton in compound **1** were consistent with the literature data, whereas values of C-1''–C-6'' for the glucosyl moiety were shifted by −1.98, +6.72, +0.21, −0.15, −1.61, and +5.37 ppm, respectively (Table 1). These findings suggested that the glucosyl moiety was linked to C-7 of the pinocembrin skeleton and two rhamnosyl moieties were connected to C-2'' and C-6'' of the glucosyl moiety.¹³ In the heteronuclear multiple-bond correlation (HMBC) spectrum, long-range correlations from H-1'' (δ_{H} 5.17) to C-7 (δ_{C} 164.90), from H-1''' (δ_{H} 5.07) to C-2'' (δ_{C} 79.76), and from H-1'''' (δ_{H} 4.52) to C-6'' (δ_{C} 65.94) were observed, confirming the aforementioned connections. Furthermore, the proton and carbon values of three sugar moieties in




Figure 1. Structures of compounds 1–7 from the seeds of *L. chinensis*.

Table 2. Cytotoxic Activity of Compounds 1–7 (IC_{50} , μM)

compounds	A549	LAC	Hep-G2	HeLa
1	57.38	0.79	0.030	23.98
2	>100	>100	>100	37.64
3	>100	>100	>100	>100
4	17.50	11.58	4.22	1.82
5	0.53	7.93	0.020	0.051
6	>100	>100	>100	>100
7	>100	>100	>100	>100
admycin	15.15	20.48	79.50	22.64

compound 1 were consistent with those of apigenin 7-*O*-(2'',6''-di- α -L-rhamnopyranosyl)- β -D-glucopyranoside.¹³ Accordingly, compound 1 was determined to be (–)-pinocembrin 7-*O*-(2'',6''-di- α -L-rhamnopyranosyl)- β -D-glucopyranoside (Figure 1), which was a new flavonone glycoside and trivially named litchioside D.

The isolated known compounds were identified as (–)-pinocembrin 7-*O*-neohesperidoside (2),^{14,15} (–)-pinocembrin 7-*O*-rutinoside (3),¹⁶ taxifolin 4'-*O*- β -D-glucopyranoside (4),¹⁷ kaempferol 7-*O*-neohesperidoside (5),¹⁸ tamarixetin 3-*O*-rutinoside (6),¹⁹ and phlorizin (7)^{20,21} by interpretation of their spectroscopic data (¹H and ¹³C NMR and ESIMS) and by comparison to reported data. Among them, compounds 3–7 were isolated from this species for the first time.

Cytotoxic Activity. The *in vitro* cytotoxic activity of seven isolated flavonoid glycosides was evaluated against human lung cancer A549, human pulmonary carcinoma LAC, human hepatoma Hep-G2, and human cervical carcinoma HeLa cell lines using the MTT colorimetric assay.¹² Their IC_{50} values on the viability of aforementioned cancer cell lines after 72 h of incubation were presented in Table 2. Kaempferol 7-*O*-neohesperidoside (5) exhibited significant cytotoxic activity against all of the test cell lines, with IC_{50} values of 0.53, 7.93, 0.020, and 0.051 μM , respectively, which were more potent than the reference compound admycin. Litchioside D (1) also showed potent activity against LAC and Hep-G2 cells (IC_{50} = 0.79 and 0.030 μM). Taxifolin 4'-*O*- β -D-glucopyranoside (4) demonstrated moderate

activity against all four cell lines, with IC_{50} values ranging from 1.82 to 17.58 μM . However, the other flavonoid glycosides (2, 3, 6, and 7) were inactive (IC_{50} > 100 μM), except that compound 2 showed a weak activity against the HeLa cell line. It is noted that the moderate activity of compound 2 against P-388 lymphocytic leukemia, with an IC_{50} value of 2.58 $\mu g/mL$ (= 4.57 μM), was previously reported,²² while the activity of compounds 1, 4, and 5 against A549, LAC, Hep-G2, and HeLa cancer cells is reported for the first time. The discovery of the cytotoxic compounds 1, 4, and 5 suggested that they might also be involved in the antitumor activity of lychee seeds.

It is worth noting that the isolated known compounds were found to have other biological activities according to literature reports. (–)-Pinocembrin 7-*O*-neohesperidoside (synonym: onychin, 2) showed biological activities of inhibiting the proliferation of vascular smooth muscle cells and preventing H₂O₂-induced apoptosis in ECV304 endothelial cells.^{23,24} Tamarixetin 3-*O*-rutinoside (6) demonstrated inhibitory activity against osteoclast differentiation by 40 and 63% at the concentrations of 0.1 and 1.0 $\mu g/mL$.²⁵ The dihydrochalcone phlorizin (7) was a natural product and dietary constituent found in a number of fruit trees, and its principal pharmacological action was to produce renal glucosuria and block intestinal glucose absorption through inhibition of the sodium–glucose symporters located in the proximal renal tubule and mucosa of the small intestine.²⁶

In conclusion, seven flavonoid glycosides were isolated in purity from the seeds of lychee (*L. chinensis* var. Heiye). Their structures were identified by the spectroscopic method, including NMR and HRESIMS. Litchioside D (1) was a new flavonone triglycoside. The known ones, except (–)-pinocembrin 7-*O*-neohesperidoside (2), were obtained from this species for the first time. Among these flavonoid glycosides, kaempferol 7-*O*-neohesperidoside (5) possessed more potent *in vitro* cytotoxic activity against A549, LAC, Hep-G2, and HeLa cancer cells than admycin and litchioside D (1) and taxifolin 4'-*O*- β -D-glucopyranoside (4) also showed the activity toward the test cell lines, suggesting that they could be contributors to the antitumor activity of lychee seeds.

■ AUTHOR INFORMATION

Corresponding Author

*Telephone/Fax: +86-20-37252537. E-mail: xiehaih@scbg.ac.cn.

Funding Sources

This work was supported by the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-218 and KSCX2-EW-J-28) and a SCBG Fund for Talented Young Scholars (SCBG200720).

■ REFERENCES

- (1) Chinese Pharmacopoeia Commission. *Pharmacopoeia of the People's Republic of China*; People's Medical Publishing House: Beijing, China, 2005; Vol. 1, p 169.
- (2) Liu, L.; Xie, B.; Cao, S.; Yang, E.; Xu, X.; Guo, S. A-type procyanidins from *Litchi chinensis* pericarp with antioxidant activity. *Food Chem.* **2007**, *105*, 1446–1451.
- (3) Chen, Y. B.; Wu, K. S.; Gu, Y.; Chen, J. Z. Research progress in the chemical constituents and pharmacological effects of lychee seeds. *Chin. J. Inf. TCM* **2007**, *14*, 97–98.
- (4) Xiao, L. Y.; Zhang, D.; Feng, Z. M.; Chen, Y. W.; Zhang, H.; Lin, P. Y. Studies on the antitumor effect of lychee seeds in mice. *J. Chin. Med. Mater.* **2004**, *27*, 517–518.
- (5) Prasad, K. N.; Yang, B.; Yang, S.; Chen, Y.; Zhao, M.; Ashraf, M.; Jiang, Y. Identification of phenolic compounds and appraisal of antioxidant and antityrosinase activities from litchi (*Litchi sinensis* Sonn.) seeds. *Food Chem.* **2009**, *116*, 1–7.
- (6) Ding, L.; Wang, M.; Zhao, J.; Du, L. Studies on chemical constituents in seed of *Litchi chinensis* Sonn. *Nat. Prod. Res. Dev.* **2006**, *18* (Supplement), 45–47.
- (7) Tu, P.; Luo, Q.; Zheng, J. Studies on chemical constituents in seed of *Litchi chinensis*. *Chin. Tradit. Herb. Drugs* **2002**, *33*, 300–303.
- (8) Xu, X.; Xie, H.; Hao, J.; Jiang, Y.; Wei, X. Eudesman sesquiterpene glucosides from lychee seed and their cytotoxic activity. *Food Chem.* **2010**, *123*, 1123–1126.
- (9) Xu, X.; Xie, H.; Wang, Y.; Wei, X. A-type proanthocyanidins from lychee seeds and their antioxidant and antiviral activities. *J. Agric. Food Chem.* **2010**, *58*, 11667–11672.
- (10) Chien, P. J.; Sheu, F.; Shyu, Y. T. Monitoring enzymatic debittering in grapefruit juice by high performance liquid chromatography. *J. Food Drug Anal.* **2001**, *9*, 115–120.
- (11) Feng, H.; Wang, Z.; Dong, G. Y.; Wu, Z. Study on chemical constituents of *Penthorum chinensis*. *Zhongguo Zhongyao Zazhi* **2001**, *26*, 260–261.
- (12) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63.
- (13) Pieroni, A.; Pachaly, P. Isolation and structure elucidation of ligustroflavone, a new apigenin triglycoside from the leaves of *Ligustrum vulgare* L. *Pharmazie* **2000**, *55*, 78–80.
- (14) Pomilio, A. B.; Gros, E. G. Pinocembrin 7-neohesperidoside from *Nierembergia hippomanica*. *Phytochemistry* **1979**, *18*, 1410–1411.
- (15) Ripperger, H. 4'''-O-Acetylsarotanoside, a novel flavanone glycoside from *Nierembergia hippomanica*. *Phytochemistry* **1981**, *20*, 1757–1758.
- (16) Kapetanidis, J.; Kokkalou, E. Flavonoides des parties aériennes de *Ziziphora taurica* Marsch. Bieb. ssp. *cleonioides* (Boiss.) P. H. Davis (Lamiaceae). *Pharm. Acta Helv.* **1988**, *63*, 206–208.
- (17) Fossen, T.; Pedersen, A.; Andersen, Ø. M. Flavonoids from red onion (*Allium cepa*). *Phytochemistry* **1998**, *47*, 281–285.
- (18) Rizwani, G. H.; Usmanhany, K.; Ahmad, M.; Ahmad, V. U. Flavone glycosides of *Caralluma tuberculata* E. Brown. *Pak. J. Pharm. Sci.* **1990**, *3*, 27–32.
- (19) Peng, E. J.; Li, Y. W.; Zhu, C. S.; Han, X. W.; Yu, B. Synthesis of tamarixetin and isorhemitin 3-O-neohesperidoside. *Carbohydr. Res.* **2005**, *340*, 1682–1688.
- (20) Qin, X. D.; Liu, J. K. A new sweet dihydrochalcone-glucoside from leaves of *Litocarpus pachyphyllus* (Kurz) Rehd. (Fagaceae). *Z. Naturforsch., C: J. Biosci.* **2003**, *58*, 759–761.
- (21) Nie, R. L.; Takashi, T.; Zhou, J.; Tanaka, O. Phlorizin and trilobatin, sweet dihydrochalcone-glucosides from leaves of *Lithocarpus litseifolius* (Hance) Rehd. (Fagaceae). *Agric. Biol. Chem.* **1982**, *46*, 1933–1934.
- (22) Xu, Y.; Kubo, I.; Ma, Y. A cytotoxic flavanone glycoside from *Onychium japonicum*: Structure of onychin. *Phytochemistry* **1993**, *33*, 510–511.
- (23) Yang, M.; Huang, H.; Zhu, B.; Tuo, Q.; Liao, D. Onychin inhibits proliferation of vascular smooth muscle cells by regulating cell cycle. *Acta Pharmacol. Sin.* **2005**, *26*, 205–211.
- (24) Tuo, Q.; Wang, C.; Yan, F. X.; Liao, D. F. MAPK pathway mediates the protective effect of onychin on oxidative stress-induced apoptosis in ECV304 endothelial cells. *Life Sci.* **2004**, *76*, 487–497.
- (25) Yoon, K. D.; Jeong, D. G.; Hwang, Y. H.; Ryu, J. M.; Kim, J. Inhibitors of osteoclast differentiation from *Cephalotaxus koreana*. *J. Nat. Prod.* **2007**, *70*, 2029–2032.
- (26) Ehrenkranz, J. R. L.; Lewis, N. G.; Kahn, C. R.; Roth, J. Phlorizin: A review. *Diabetes/Metab. Res. Rev.* **2005**, *21*, 31–38.